Interrupting ER signaling has been one of the most successful therapeutic strategies in cancer therapy, among which TAM has been the most widely administered endocrine therapy for ER+ breast cancer, especially for premenopausal women patients [28]. Here, ESR1 is linked to breast carcinoma.